• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期暴露于生物相容性、高渗、丙酮酸缓冲透析液的实验研究。

Experimental study on long-term exposure to a biocompatible, hypertonic, pyruvate-buffered dialysis solution.

作者信息

van Westrhenen Roos, Vlijm Anniek, Hiralall Johan K, Krediet Raymond T

机构信息

Department of Nephrology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

出版信息

Perit Dial Int. 2008 Nov;28 Suppl 5:S43-7.

PMID:19008540
Abstract

BACKGROUND

Chronic exposure to glucose and glucose degradation products (GDPs) in dialysis solutions is involved in the pathogenesis of peritoneal neoangiogenesis and fibrosis, potentially leading to encapsulating peritoneal sclerosis (EPS). High lactate concentrations may contribute to glucose toxicity by creating a state of pseudohypoxia, which stimulates the formation of various growth factors.

OBJECTIVE

To study the effects of long-term peritoneal exposure to a filter-sterilized pyruvate-buffered solution with a combination of 3 osmotic agents (amino acids, glycerol, glucose: PYRAGG) on peritoneal function and morphology.

METHODS

Rats were exposed daily for a period of 20 weeks to PYRAGG, or to a conventional heat-sterilized solution (LH), or to a filter-sterilized solution (LF), after which a peritoneal function test was done and peritoneal tissue was obtained.

RESULTS

Peritoneal solute and fluid transport characteristics at 20 weeks were similar in all groups. Fibrosis was most pronounced in the LH group compared to the others, suggesting an effect of GDPs. A marked reduction in the number of omental vessels was noted in the PYRAGG group (59% reduction compared to LH). A modest reduction (28%) was found in the LF animals. This points to a marked effect of reduced exposure to glucose.

CONCLUSIONS

PYRAGG was more biocompatible than a filter-sterilized glucose/lactate solution because it did not induce marked peritoneal abnormalities after long-term exposure. This did not lead to altered peritoneal transport characteristics. It is likely that further development of PYRAGG-like solutions will decrease the incidence of EPS.

摘要

背景

透析液中长期暴露于葡萄糖和葡萄糖降解产物(GDPs)参与腹膜新生血管形成和纤维化的发病机制,可能导致包裹性腹膜硬化(EPS)。高乳酸浓度可能通过产生假缺氧状态促进葡萄糖毒性,从而刺激各种生长因子的形成。

目的

研究长期腹膜暴露于含3种渗透剂(氨基酸、甘油、葡萄糖:PYRAGG)组合的过滤除菌丙酮酸缓冲溶液对腹膜功能和形态的影响。

方法

大鼠每日暴露于PYRAGG、传统热消毒溶液(LH)或过滤除菌溶液(LF)20周,之后进行腹膜功能测试并获取腹膜组织。

结果

20周时所有组的腹膜溶质和液体转运特征相似。与其他组相比,LH组纤维化最为明显,提示GDPs的作用。PYRAGG组网膜血管数量显著减少(与LH组相比减少59%)。LF组动物有适度减少(28%)。这表明减少葡萄糖暴露有显著作用。

结论

PYRAGG比过滤除菌的葡萄糖/乳酸溶液生物相容性更好,因为长期暴露后它不会引起明显的腹膜异常。这并未导致腹膜转运特征改变。类似PYRAGG溶液的进一步研发可能会降低EPS的发生率。

相似文献

1
Experimental study on long-term exposure to a biocompatible, hypertonic, pyruvate-buffered dialysis solution.长期暴露于生物相容性、高渗、丙酮酸缓冲透析液的实验研究。
Perit Dial Int. 2008 Nov;28 Suppl 5:S43-7.
2
Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.长期接触新型腹膜透析液:对腹膜的影响。
Kidney Int. 2004 Sep;66(3):1257-65. doi: 10.1111/j.1523-1755.2004.00879.x.
3
The effects of a dialysis solution with a combination of glycerol/amino acids/dextrose on the peritoneal membrane in chronic renal failure.甘油/氨基酸/葡萄糖透析液对慢性肾衰竭患者腹膜间皮细胞的影响。
Perit Dial Int. 2010 Mar-Apr;30(2):192-200. doi: 10.3747/pdi.2008.00159. Epub 2010 Feb 1.
4
Heat sterilization of peritoneal dialysis solutions influences ingestive behavior in non-uremic rats.腹膜透析液的热消毒会影响非尿毒症大鼠的摄食行为。
Kidney Int. 2002 Oct;62(4):1447-53. doi: 10.1111/j.1523-1755.2002.kid575.x.
5
Better preservation of the peritoneum in rats exposed to amino acid-based peritoneal dialysis fluid.在暴露于氨基酸基腹膜透析液的大鼠中,腹膜的保存情况更佳。
Perit Dial Int. 2005 Jan-Feb;25(1):58-67.
6
Effects of acidity, glucose degradation products, and dialysis fluid buffer choice on peritoneal solute and fluid transport in rats.酸度、葡萄糖降解产物及透析液缓冲液选择对大鼠腹膜溶质和液体转运的影响
Perit Dial Int. 1998 May-Jun;18(3):303-10.
7
BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].儿童生物相容性腹膜透析液中碳酸氢盐与乳酸盐缓冲剂比较的随机对照试验[国际标准随机对照试验编号:ISRCTN81137991]
BMC Nephrol. 2004 Oct 14;5:14. doi: 10.1186/1471-2369-5-14.
8
Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH.碳酸氢盐/乳酸缓冲的PDF生物相容性的改善与pH无关。
Nephrol Dial Transplant. 2006 Jan;21(1):208-16. doi: 10.1093/ndt/gfi188. Epub 2005 Nov 1.
9
Vasoactive components of dialysis solution.透析液的血管活性成分。
Perit Dial Int. 2008 May-Jun;28(3):283-95.
10
Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution.长期暴露于碳酸氢盐/乳酸缓冲溶液后,大鼠腹膜形态特征及防御功能的保存情况更佳。
J Am Soc Nephrol. 2001 Dec;12(12):2775-2786. doi: 10.1681/ASN.V12122775.

引用本文的文献

1
Advantages of pyruvate-based fluids in preclinical shock resuscitation-A narrative review.基于丙酮酸的液体在临床前休克复苏中的优势——一篇叙述性综述。
Front Physiol. 2022 Nov 21;13:1027440. doi: 10.3389/fphys.2022.1027440. eCollection 2022.
2
How to Improve the Biocompatibility of Peritoneal Dialysis Solutions (without Jeopardizing the Patient's Health).如何提高腹膜透析液的生物相容性(同时不损害患者健康)。
Int J Mol Sci. 2021 Jul 26;22(15):7955. doi: 10.3390/ijms22157955.
3
Peritoneal dialysis: from bench to bedside.腹膜透析:从实验台到临床应用
Clin Kidney J. 2013 Dec;6(6):568-77. doi: 10.1093/ckj/sft122. Epub 2013 Oct 14.
4
Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.在接受腹膜透析的患者中,葡萄糖降解产物含量低的中性溶液与较少的腹膜纤维化和血管硬化有关。
Perit Dial Int. 2013 May-Jun;33(3):242-51. doi: 10.3747/pdi.2011.00270. Epub 2012 Nov 1.
5
Pharmacology of sclerotherapy.硬化疗法的药理学
Semin Intervent Radiol. 2010 Dec;27(4):391-9. doi: 10.1055/s-0030-1267848.
6
Update on potential medical treatments for encapsulating peritoneal sclerosis; human and experimental data.包裹性腹膜硬化症的潜在治疗方法的最新进展;人体和实验数据。
Int Urol Nephrol. 2011 Mar;43(1):147-56. doi: 10.1007/s11255-010-9744-5. Epub 2010 May 7.